CN103933195B - A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine - Google Patents
A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine Download PDFInfo
- Publication number
- CN103933195B CN103933195B CN201410097271.3A CN201410097271A CN103933195B CN 103933195 B CN103933195 B CN 103933195B CN 201410097271 A CN201410097271 A CN 201410097271A CN 103933195 B CN103933195 B CN 103933195B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- chinese medicine
- medicine composition
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a kind of Chinese medicine composition treating hepatopathy, by Radix Glycyrrhizae extract, silymarin, Radix Salviae Miltiorrhizae extract, Herba Sedi extract, soybean phospholipid, Fructus Schisandrae Chinensis extrat forms, this Chinese medicine composition can alleviate hepar damnification, reduces transaminase, for acute, chronic hepatitis, medicamentous liver lesion, fatty liver, alcoholic liver damage.
Description
Technical field
The invention belongs to Chinese medicine and field of pharmaceutical preparations, be specifically related to a kind of Chinese medicine composition, this Chinese medicine composition is used for
Hepar damnification can be alleviated, reduce transaminase, for acute, chronic hepatitis, medicamentous liver lesion, fatty liver, alcoholic liver damage.
Background technology
Hepatic disease generallys include liver dysfunction, hepatitis, liver cirrhosis, hepatocarcinoma etc..By hepatitis virus cause viral
One of hepatitis infectious disease that always whole world is serious, sick since the commonly encountered diseases of China and frequently-occurring disease, especially the seventies especially
The incidence rate of virus hepatitis remains high so that it is patient groups is more and more big, and viral hepatitis as common in hepatitis B, hepatitis C etc. is
Become clinical difficult treatment, the most become the main inducing of liver cirrhosis, onset of liver cancer.Owing to the cause of disease of this class disease is more, sick
Poison is turned out cloudy difficulty, and the course of disease is longer, and it is poor that some patients lapses to prognosis, causes huge body and mind to patient painful.Up to now,
More for treating the medicine of acute, chronic hepatitis clinically, doctor trained in Western medicine is mainly from sides such as antiviral, regulation immunity and liver function protectings
Face is treated, and the traditional Chinese medical science is then started with treatment from determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.In terms of clinical practice, Chinese and Western in terms of improving liver function and liver function protecting
The aspects such as medicine all has certain curative effect, but at Shorten the Treatment Process, promotes that virus is turned out cloudy, prevention liver cirrhosis, medicine so far is the most not
Fully up to expectations.Particularly at present in terms of improving liver function, some patients is not the best enough to current medication effect, many medicines
Thing only acts on the pathogenetic aspect of liver damage, it is therefore desirable to provide effectively for clinical liver disease, efficiently, long-acting,
Safe and reliable, the new drug for the treatment of both the principal and secondary aspects of a disease, it is still problem in the urgent need to address.
Summary of the invention
It is an object of the invention to provide a kind of Chinese medicine composition, by Radix Glycyrrhizae extract 2～8 parts, silymarin 10～50
Part, Radix Salviae Miltiorrhizae extract 2～7 parts, Herba Sedi extract 10～40 parts, soybean phospholipid 30～60 parts and Fructus Schisandrae Chinensis extrat 1～5 parts
Composition, is in parts by weight.
Preferably, the Chinese medicine composition of the present invention, Radix Glycyrrhizae extract 3～7 parts, silymarin 10～40 parts, Radix Salviae Miltiorrhizae carry
Take thing 2～5 parts, Herba Sedi extract 20～40 parts, soybean phospholipid 30～50 parts and Fructus Schisandrae Chinensis extrat 1～3 parts of compositions.
It is furthermore preferred that the Chinese medicine composition of the present invention, by Radix Glycyrrhizae extract 5 parts, silymarin 20 parts, Radix Salviae Miltiorrhizae extract 3
Part, Herba Sedi extract 30 parts, soybean phospholipid 40 parts and Fructus Schisandrae Chinensis extrat 2 parts composition.
The Chinese medicine composition of the invention described above, loads capsule and takes after pulverizing.
Another object of the present invention provides a kind of traditional Chinese medicine preparation, comprises the Chinese medicine composition of the present invention and medicinal auxiliary
Material.Described pharmaceutic adjuvant is the most originally field customary adjuvant, and described pharmaceutic adjuvant is selected from filler, disintegrating agent, binding agent, lubricant
Any mixture with them.
The traditional Chinese medicine preparation of the invention described above, its dosage form is tablet, capsule, oral liquid, pill, injection etc..
The traditional Chinese medicine preparation of the invention described above, described filler is selected from starch, microcrystalline Cellulose, ethyl cellulose, first
Base cellulose, mannitol and pregelatinized Starch, disintegrating agent forms sediment selected from polyvinylpolypyrrolidone, low-substituted hydroxypropyl methylcellulose, carboxymethyl
Powder sodium and sodium carboxymethyl cellulose, binding agent is selected from hypromellose, polyvidone, starch, gelatin etc., and lubricant is Pulvis Talci
Or magnesium stearate.
A further object of the present invention there are provided the Chinese medicine composition of the present invention and prevents and treats in hepatopathy medicine in manufacture
Application.
The application of the invention described above, described hepatopathy includes liver function and hepar damnification, transaminase's rising, acute and chronic liver
Inflammation, medicamentous liver lesion, fatty liver or alcoholic liver damage.
The Traditional Chinese medicine composition of the present invention, at liver function protecting, alleviates hepar damnification, and reducing transaminase's aspect has well
Effect, simultaneously, it may also be used for acute, chronic hepatitis, medicamentous liver lesion, fatty liver, the treatment of alcoholic liver damage, its effect
Substantially.
The Chinese medicine composition of the invention described above, described silymarin and soybean phospholipid buy from commercial channels, described Radix Glycyrrhizae
Extract, Herba Sedi extract, Radix Salviae Miltiorrhizae extract, Fructus Schisandrae Chinensis extrat are the most commercially buied, it is possible to logical following methods
It is prepared.
Radix Salviae Miltiorrhizae extract: take Radix Salviae Miltiorrhizae, is ground into coarse powder, adds alcohol heating reflux and extracts three times, filters, merging filtrate, subtract
Pushing back receipts ethanol and to be condensed into relative density be 1.30～1.35 (60 DEG C) thick paste, be washed till washing liquid with hot water colourless, 80 DEG C are dried,
It is ground into fine powder, to obtain final product.
Fructus Schisandrae Chinensis extrat: take schisandra chinensis medicinal material decocting in water secondary, each 1～2 hour, filters, and obtains medicinal residues → use again
80% ethanol extraction, filters, filtrate waves most alcohol, with water precipitation, takes precipitation, true with 80% ethanol extraction, concentration ethanol, concentrate
Sky is drying to obtain.
Herba Sedi extract: take Herba Sedi and be ground into coarse powder, with 50～90% ethanol extraction 1～5 times, each 0～5 is little
Time, merge ethanol extract, be evaporated to 60 DEG C and measure the extractum that relative density is 1.25～1.30, standby；Medicinal residues add 8 times
The soak by water 1 of amount～5 times, each 1～3 hour, filter, merging filtrate, and filtrate is concentrated into thick paste, thick by above-mentioned ethanol extraction
The thick paste that cream carries with water mixes, and vacuum drying is standby and get final product.
Radix Glycyrrhizae extract: extracting liquorice cleans, be dried, pulverize after, adds the water reflux, extract, 3 times of 4～5 times, each 2h, conjunction
And extracting solution, it being concentrated into the 1/5 of original volume, filter, filtrate continues to concentrate, and concentrated solution 140～160 DEG C of spray drying obtain sweet
Grass extract.
The Chinese medicine composition of the invention described above, be configured to medicinal liquid or be ground into granule load capsule can directly be administered orally, one day 3
Secondary.
The traditional Chinese medicine preparation of the present invention can use the conventional method in existing pharmaceutical field to produce, permissible the when of needs
Add various pharmaceutically acceptable pharmaceutic adjuvant.Described adjuvant includes the diluent of pharmaceutical field routine, excipient, filling
Agent, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant etc..Described filler has:
Starch, Icing Sugar, calcium phosphate, calcium sulfate two water thing, dextrin, microcrystalline Cellulose, lactose, pregelatinized Starch, mannitol etc.；Described viscous
Mixture has: sodium carboxymethyl cellulose, PVP～K30, hydroxypropyl cellulose, starch slurry, methylcellulose, ethyl cellulose, hydroxypropyl
Methylcellulose, pregelatinized Starch etc.；Described disintegrating agent has: dried starch, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxylic first
Base Starch Sodium, low-substituted hydroxypropyl cellulose etc.；Described lubricant has: magnesium stearate, Pulvis Talci, sodium lauryl sulphate, micro-
Powder silica gel etc..
When pharmaceutical preparation of the present invention is injection, in order to increase its dissolubility, the cosolvents such as polyoxyethylene sorbitan monoleate can be added.
Transfusion can add the isoosmotic adjusting agent for regulating osmotic pressure, such as, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, breast
Acid sodium, glucose, xylitol, sorbitol and dextran etc., preferably glucose.Powder pin can add excipient, such as, manna
Alcohol, glucose, lactose, dextran, sorbitol, sucrose, glycine, sodium chloride etc..
The advantage of the Traditional Chinese medicine composition of the present invention or beneficial healing effect: the Chinese medicine composition of the present invention is improving liver
Function and liver function protecting aspect effect are notable, and curative effect is obvious, but also can preventing liver injury, preventing and treating fatty liver.Therefore, this
Bright Chinese medicine composition can be used for prevent and treat hepatic injury, reduce transaminase, for acute, chronic hepatitis, medicamentous liver lesion, fatty liver,
The treatment of alcoholic liver damage.The Chinese medicine composition of the present invention, patient daily 1500～4500mg, 2000～3000mg,
Divide and take for 2～3 three times.
Detailed description of the invention
Following example are for being further elucidated with or understand the essence of the present invention, but do not limit the scope of the present invention with this.
Embodiment 1
Prescription:
Radix Glycyrrhizae extract 55mg, silymarin 250mg, Radix Salviae Miltiorrhizae extract 30mg, Herba Sedi extract 250mg, Semen sojae atricolor phosphorus
Fat 400mg, Fructus Schisandrae Chinensis extrat 15mg.
Preparation method: the extract of above-mentioned recipe quantity, silymarin and soybean phospholipid are mixed, is ground into fine grained, mixed
Close uniformly, load in capsule.Patient takes, oral administration, 3 times on the one, each 1g.
Embodiment 2
Radix Glycyrrhizae extract 50g, Herba Silybi mariani extract 200g, Radix Salviae Miltiorrhizae extract 30g, Herba Sedi extract 300g, Semen sojae atricolor phosphorus
Fat 400g, Fructus Schisandrae Chinensis extrat 20g.
Preparation method: the extract by above-mentioned recipe quantity of recipe quantity, silymarin and soybean phospholipid are mixed, is ground into
Fine powder, sieves, and adds size-reduced and after sieving 300g microcrystalline Cellulose, 150g polyvinylpolypyrrolidone and 50g magnesium stearate, mixed
Closing, to uniformly, the polyvidone ethanol solution adding appropriate 10% is pelletized, granulate, tabletting, totally 4000.Take three every day to owe, often
Secondary 3～4.
Embodiment 3
Prescription
Radix Glycyrrhizae extract 40mg, Herba Silybi mariani extract 300mg, Radix Salviae Miltiorrhizae extract 45mg, Herba Sedi extract 200mg, big
Fabaceous lecithin 500mg, Fructus Schisandrae Chinensis extrat 15mg.
Embodiment 4
Prescription
Radix Glycyrrhizae extract 40mg, Herba Silybi mariani extract 300mg, Radix Salviae Miltiorrhizae extract 40mg, Herba Sedi extract 250mg, big
Fabaceous lecithin 450mg, Fructus Schisandrae Chinensis extrat 20mg.
Preparation method: after the medicine of above-mentioned recipe quantity is pulverized, becomes solution or suspension with water dissolution, oral administration, one day 3
Secondary.The most above-mentioned unit 1g.
Embodiment 5～9
Prescription
| Composition | Embodiment 5 | Embodiment 6 | Embodiment 7 | Embodiment 9 |
| Radix Glycyrrhizae extractum (mg) | 55 | 50 | 40 | 40 |
| Silymarin (mg) | 250 | 200 | 300 | 300 |
| Radix Salviae Miltiorrhizae extract (mg) | 30 | 30 | 45 | 40 |
| Herba Sedi extract (mg) | 250 | 200 | 200 | 250 |
| Soybean phospholipid (mg) | 400 | 500 | 500 | 450 |
| Fructus Schisandrae Chinensis extrat (mg) | 20 | 20 | 15 | 20 |
Embodiment 3～9, by the method for embodiment 1 or 2, is prepared as capsule or tablet.
Embodiment 10
Pharmacodynamics test
Choose 8 week old male SD rats, body weight about about 200g, experiment the most random point 3 groups, respectively blank group,
Matched group, experimental group.Adaptability nursing rat is after 1 week, and often group is pressed random digits table and selected 20.Blank group is fed with general
Logical feedstuff.Matched group and experimental group often organize use rat 20, and acute hepatic injury model uses D～Galactosamine-induced Liver Damage mould
Type, gavage, to 0.5%CMC solution (150mg/kg), is given daily 1 time, and successive administration 7d, 6d after administration, except blank
Outside group, remaining each group of mice equal lumbar injection D～galactosamine 0.8g/kg.After last is administered 16h, rat vena ophthalmica clump takes blood, point
From serum, measure the liver function indexs such as serum alt, AST, bilirubin, albumin.The Chinese medicine of the experimental group daily present invention
Compositions, three times a day, takes blood examination according to 160mg/kg (people and rat commonly use conversion amount) respectively at taking latter 3 days, 7 days, 14 days
Surveying liver function, result prompting can substantially reduce transaminase, improve liver function.
Table 1: medication treatment is liver function situation after 3 days
Table 2: medication treatment is liver function situation after 7 days
Table 3: medication treatment is liver function situation after 14 days
The animal test results of above table 1～3 shows: the Chinese medicine composition of the present invention is protecting the liver the advantageous effect of aspect
It is: owing to the pathogenesis of abnormal liver function liver damage has multiple, such as liver plasma membrane loss, Free radicals injury, inflammation
The number of mechanisms such as abnormal reaction, transaminase's release, the most conventional hepatic is many for one of which mechanism, therefore to part
Effect is not ideal enough, and this Chinese medicine composition specially invented, wherein, Radix Glycyrrhizae can be alleviated and alleviate local inflammation reaction；Herba Silybi mariani
Element can be removed free radical, Scavenger of ROS, the reaction that reduces inflammation, promote hepatocellular reparation, and danshensu can improve liver
Regional flow, blood circulation promoting and blood stasis dispelling；Herba Sedi can heat-clearing and toxic substances removing, eliminating damp-heat, cell immune response can be significantly inhibited thus alleviate
The inflammatory reaction of liver, has reduction glutamate pyruvate transaminase effect；Soybean phospholipid can combine with liver plasma membrane and organelle film, passes through
Directly affecting membrane structure makes impaired liver function and enzyme activity recover normal, promotes hepatic tissue regeneration, by solid to neutral fat and gallbladder
Alcohol changes into the form of easy metabolism, thus can improve liver function, treats fatty liver.Fructus Schisandrae Chinensis extrat energy antagonism oxygen is freely
Base damages, and stimulates the anabolism of liver and strengthens the activity of Cytochrome P450.Therefore, the Chinese medicine composition of the present invention is changing
Kind liver function and liver function protecting aspect effect are notable, and curative effect is obvious.
Claims (8)
1. a Chinese medicine composition, by Radix Glycyrrhizae extract 2～8 parts, silymarin 10～50 parts, Radix Salviae Miltiorrhizae extract 2～7 parts, hangs down
Basin grass extract 10～40 parts, soybean phospholipid 30～60 parts and Fructus Schisandrae Chinensis extrat 1～5 parts of compositions, be in parts by weight.
2. Chinese medicine composition as claimed in claim 1, is carried by Radix Glycyrrhizae extract 3～7 parts, silymarin 10～40 parts, Radix Salviae Miltiorrhizae
Take thing 2～5 parts, Herba Sedi extract 20～40 parts, soybean phospholipid 30～50 parts and Fructus Schisandrae Chinensis extrat 1～3 parts of compositions.
3. Chinese medicine composition as claimed in claim 2, by Radix Glycyrrhizae extract 5 parts, silymarin 20 parts, Radix Salviae Miltiorrhizae extract 3 parts,
Herba Sedi extract 30 parts, soybean phospholipid 40 parts and Fructus Schisandrae Chinensis extrat 2 parts composition.
4. a traditional Chinese medicine preparation, comprises the Chinese medicine composition described in any one of claims 1 to 3 and pharmaceutic adjuvant.
5. preparation as claimed in claim 4, described pharmaceutic adjuvant selected from filler, disintegrating agent, binding agent, lubricant and they
Any mixture.
6. the Chinese medicine composition described in any one of claims 1 to 3 prevents and treats the application in hepatopathy medicine in manufacture.
Applying the most as claimed in claim 6, described hepatopathy is liver function and hepar damnification.
Apply the most as claimed in claim 7, described liver function and hepar damnification be transaminase raise, acute, chronic hepatitis, medicine
Physical property hepatic injury, fatty liver or alcoholic liver damage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410097271.3A CN103933195B (en) | 2014-03-17 | 2014-03-17 | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410097271.3A CN103933195B (en) | 2014-03-17 | 2014-03-17 | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103933195A CN103933195A (en) | 2014-07-23 |
| CN103933195B true CN103933195B (en) | 2016-08-17 |
Family
ID=51181252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410097271.3A Expired - Fee Related CN103933195B (en) | 2014-03-17 | 2014-03-17 | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933195B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623048B (en) * | 2014-12-23 | 2017-05-24 | 河南省帝一方生物制药有限公司 | Chinese medicinal compound preparation for protecting liver and removing mildew and preparation method of Chinese medicinal compound preparation |
| CN106492032A (en) * | 2016-12-06 | 2017-03-15 | 衡阳茂晨农业开发有限公司 | A kind of Chinese medicine composition of preventing and treating Rana grylia infectious liver disease and preparation method thereof |
| KR101853603B1 (en) * | 2017-05-18 | 2018-05-02 | 주식회사 쎌바이오텍 | Composition containing of probiotics for using alcohol or acetaldehyde dehydrogenase activity |
-
2014
- 2014-03-17 CN CN201410097271.3A patent/CN103933195B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 皮肤科易致肝损伤药物及其所致肝损伤的中西药治疗;孙云芸等;《吉林中医药》;20120630;第32卷(第6期);第623页3.2.1，第623页3.1.3、第624页3.2.2、3.2.3、左栏第3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103933195A (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004530634A (en) | Novel pharmaceutical herbal composition for treating liver disease and HIV | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN103933195B (en) | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN103751450A (en) | Composition for treating diabetic nephropathy | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN106362088A (en) | Traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis | |
| CN1814153A (en) | Medicine composition for preventing and treating breast cancer and preparing method | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN104491741A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN102327369B (en) | Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof | |
| CN104758827B (en) | A kind of composition of medicine for being used to treat acute viral hepatitis | |
| CN1618430A (en) | Adefovir composite medicine for treating hepatitis B | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN102895513B (en) | Application of Chinese medicine composition in preparing medicines for treating viral myocarditis | |
| CN101991678B (en) | Application of India madder root in preparing medicine for preventing and treating kidney disease | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN101057906B (en) | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application | |
| CN103830563B (en) | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof | |
| CN101491574A (en) | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof | |
| CN101099850A (en) | Medicine composition for treating chronic active hepatitis and early-stage hepatocirrhosis and preparation method thereof | |
| CN101700342B (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160817 Termination date: 20170317 |